HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use ZINECARD safely and effectively. See full prescribing information for ZINECARD. ZINECARD® (dexrazoxane) for injection Initial U.S. Approval: 1995 INDICATIONS AND USAGEZINECARD is a cytoprotective agent indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m2 and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use ZINECARD with doxorubicin initiation. (1) DOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHS250 mg or 500 mg single dose vials as sterile, pyrogen-free lyophilizates. (3) CONTRAINDICATIONSZINECARD should not be used with non-anthracycline chemotherapy regimens. (4) WARNINGS AND PRECAUTIONSADVERSE REACTIONSIn clinical studies, ZINECARD was administered to patients also receiving chemotherapeutic agents for cancer. Pain on injection was observed more frequently in patients receiving ZINECARD versus placebo. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. USE IN SPECIFIC POPULATIONS
See 17 for PATIENT COUNSELING INFORMATION. Revised: 10/2016 |

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
ZINECARD®(dexrazoxane)
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
ZINECARD® Quick Finder
To interact with the Medical Information Digital Assistant click here.
Contact Pfizer Medical Information to speak with a professional regarding your medical question on a Pfizer prescription product: (800) 438-1985
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns at 1-800-FDA-1088 or www.fda.gov/MedWatch